Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Allergen (AGN) PT Lowered to $200 at Mizuho Securities
January 30, 2019 8:21 AM ESTMizuho Securities analyst Irina Koffler lowered the price target on Allergen (NYSE: AGN) to $200.00 (from $213.00) while maintaining a Buy rating. Mizuho Securities raised our 2019 revenue from $15.0B to $15.1B due to continued Restasis durability in 1Q:19. Koffler also slightly lowered the tax rate (to... More
Allergan (AGN) in Final Stages of Selling Antibiotics Divisions, Plans to Keep Women's Health Unit - Bloomberg, Citing Conf. Call
January 29, 2019 8:43 AM ESTAllergan (NYSE: AGN) in Final Stages of Selling Antibiotics Divisions, Plans to Keep Women's Health Unit - Bloomberg, Citing Conf. Call
... MoreAllergan (AGN) Tops Q4 EPS by 14c, Offers Q1 and FY Guidance, Approves $2B Buyback
January 29, 2019 7:04 AM EST(Updated - January 29, 2019 7:12 AM EST)
Allergan (NYSE: AGN) reported Q4 EPS of $4.29, $0.14 better than the analyst estimate of $4.15. Revenue for the quarter came in at $4.08 billion versus the consensus estimate of $4 billion.
GUIDANCE:
Allergan sees FY2019 EPS of at least... More
